~
検索条件をクリア

International Journal of Myeloma 5巻 2号

発行元
日本骨髄腫学会
ISSN
ISSN(オンライン)
2187-3143
旧名・別名
抄録集:日本骨髄腫研究会総会 プログラム・抄録集

書籍情報から探す
開始頁
第40回日本骨髄腫学会学術集会 会長挨拶
畑裕之
第40回日本骨髄腫学会学術集会 会長, 熊本大学大学院 生命科学研究部生体情報解析学
International Journal of Myeloma 5 (2) 3-3, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY-1 Diagnosis and management of myeloma kidney
Colin Andrew Hutchison
Department of Nephrology, University, Hospital Birmingham, QEMC
International Journal of Myeloma 5 (2) 38-38, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY-2 Plasma cell dyscrasia with renal impairment including MGRS : The importance of multi-departmental management
Shinichi Mizuno
Dept. Nephrology, Japan Community Health care Organization Sendai Hospital
International Journal of Myeloma 5 (2) 39-39, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY-3 Pathophysiology and management of peripheral neuropathy in multiple myeloma and other plasma cell dyscrasias
Chiaki Nakaseko
Department of Hematology, Chiba University Hospital
International Journal of Myeloma 5 (2) 40-40, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-1 The incidence and clinical features of HBV reactivation in multiple myeloma: KTMM multicenter study
Yutaka Tsukune1, Yuriko Yahata1, Makoto Sasaki1, Hideto Tamura2, Asaka Onodera2, Michiaki Koike5, Shigeki Ito7, Yoji Ishida8, Yoichi Imai4, Junji Tanaka4, Atsushi Isoda3, Morio Matsumoto3, Sakae Tanosaki6, Norio Komatsu1
1Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, 2Division of Hematology,Department of Internal Medicine, Nippon Medical School, 3Department of Hematology, National Hospital Organization Nishigunma National Hospital, 4Department of Hematology, School of Medicine, Tokyo Women's Medical University, 5Department of Hematology, Juntendo University Shizuoka Hospital, 6Department of Hematology, The Fraternity Memorial Hospital, 7Department of Medical Oncology, Iwate Medical University School of Medicine, 8Hematology / Oncology, Iwate Medical University School of Medicine
International Journal of Myeloma 5 (2) 42-42, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-2 Evaluation of antibody against measles, rubella, mumps, and VZV in multiple myeloma (MM) patients.
Takatoshi Aoki1, Tomohiko Kamimura1, Yasuo Mori2, Kenjirou Kamezaki2, Toshihiro Miyamoto2, Koichi Akashi2
1Department of Hematology, Harasanshin Hospital, 2Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University
International Journal of Myeloma 5 (2) 43-43, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-3 Analysis of risk factors from MGUS to multiple myeloma in our hospital.
Mitsuhiro Itagaki1, Hideki Asaoku2, Yuta Katayama1, Kayo Toishigawa1, Tetsurou Ochi1, Takeshi Okatani1, Ryouta Imanaka1, Kouhei Kyo1, Kouji Iwato3, Taiichi Kyo1
1Dept. Hematology Hiroshima Red Cross Hospital, 2Dept. Laboratory Hiroshima Red Cross Hospital, 3Dept. Transfusion Hiroshima Red Cross Hospital
International Journal of Myeloma 5 (2) 44-44, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-4 A retrospective study for the evolving to symptomatic myeloma from MGUS and smoldering myeloma.
Katsuya Furukawa, Atsushi Murase, Naoyuki Tange, Masaya Hayakawa, Hiroshi Kosugi
Department of Hematology, Ogaki Municipal Hospital
International Journal of Myeloma 5 (2) 45-45, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-5 Revised ISS : Validation by the data from the multicenter study of the Japanese Society of Myeloma
Shuji Ozaki1, Takayuki Saitoh2, Hiroshi Handa3, Eiko Shibata4, Kazuyuki Shimizu5, Eiichi Nagura6
1Department of Hematology, Tokushima Prefectural Central Hospital, 2Department of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, 3Department of Hematology, Gunma University, 4Secretariat, Japanese Society of Myeloma, 5Department of Hematology, Tokai Central Hospital, 6Director, Chutoen General Medical Center
International Journal of Myeloma 5 (2) 46-46, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-6 Clinical significance of circulating plasma cells in myeloma ; 6-color flowcytometry analysis
Manabu Fujisawa, Yasuhito Suehara, Kouta Fukumoto, Hiroki Sugihara, Masami Takeuchi, Kosei Matsue
Department of Hematology-Oncology Kameda Medical Center
International Journal of Myeloma 5 (2) 47-47, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-7 Quantification of clonal circulating plasma cells by 6-color flowcytometry in plasma cell dyscrasias
Takako Motoi1, Takashi Natsuka1, Tsubasa Murata1, Manabu Fujisawa2, Kosei Matsue2
1Division of hematology section, Central laboratory, Kameda Medical center, 2Department of Hematology / Oncology, Kameda Medical Center
International Journal of Myeloma 5 (2) 48-48, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-8 A pilot study for the imaging range of FDG PET / CT for multiple myeloma
Momoko Okasaki1, Kazuo Kubota1, Yoko Miyata1, Miyako Morooka1, Risen Hirai2, Shotaro Hagiwara2, Akiyoshi Miwa2
1Division of Nuclear Medicine, National Center for Global Health and Medicine, 2Division of Hematology, National Center for Global Health and Medicine
International Journal of Myeloma 5 (2) 49-49, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-9 Impact of new agent containing induction therapy on transplant-eligible multiple myeloma patients
Shingo Okuno, Toshihiro Iwasaki, Satoshi Nishiwaki, Satomi Terabe, Yasuhiko Harada, Isamu Sugiura
Department of Hematology & Oncology, Toyohashi Municipal Hospital
International Journal of Myeloma 5 (2) 50-50, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-10 Effectiveness of autoPBSCT to MM Patients received bortezomib based regimen as an initial treatment.
Hitoshi Matsuoka1,6, Hiroshi Kawano1,6, Masanori Takeuchi1,6, Seiishi Sato2,6, Koichi Maeda3,6, Kiyoshi Yamashita4,6, Yoko Kubuki5,6, Akira Kitanaka5,6, Kazuya Shimoda5,6
1Dept. of int. med. Koga general hospital, 2Dept. of int. med. Fujimoto general hospital, 3Dept. of int. med. National Miyakonojo hospital, 4Dept. of int. med. Miyazaki prefectural hospital, 5Dept. of Gastroenterology and Hematology Faculty of Medicine, University of Miyazaki, 6Miyazaki Hematology group
International Journal of Myeloma 5 (2) 51-51, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-11 Autologous PBSCT for multiple myeloma ; a retrospective analysis of 49 cases.
Koichi Osaki, Satoko Koteda, Kuniki Kawaguchi, Kei Nomura, Takayuki Nakamura, Harumi Takeda, Satoshi Morishige, Eijiro Oku, Yuka Takata, Ritsuko Seki, Fumihiko Mouri, Koji Nagafuji
Division of Hematology and Oncology, Department of Medicine, Kurume University
International Journal of Myeloma 5 (2) 52-52, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-12 The potential benefits of allogeneic SCT for refractory MM combined with bortezomib and lenalidomide
Teppei Sakoda, Takuji Yamauchi, Toshihiro Miyamoto, Yu Kochi, Tomonori Shimokawa, Takahiro Shima, Yasuo Mori, Goichi Yoshimoto, Kenjiro Kamezaki, Koji Kato, Katsuto Takenaka, Hiromi Iwasaki, Koichi Akashi
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences
International Journal of Myeloma 5 (2) 53-53, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-13 Allogeneic stem cell transplantation for multiple myeloma : a case series in a single institution
Shotaro Hagiwara, Jun-ichiro Takano, Risen Hirai, Akira Tanimura, Akiyoshi Miwa
Division of Hematology, National Center for Global Health and Medicine
International Journal of Myeloma 5 (2) 54-54, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-14 Change of survival of myeloma in the era before and after bortezomib over 20-years period
Manabu Fujisawa, Yasuhito Suehara, Kouta Fukumoto, Hiroki Sugihara, Masami Takeuchi, Kosei Matsue
Department of Hematology-Oncology Kameda Medical Center
International Journal of Myeloma 5 (2) 55-55, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-15 Treatment of bortezomib-based regimens for transplant-ineligible NDMM : a single center experience
Masayuki Matsuda, Haruto Yamada, Tomko Inomata, Jun Konishi, Shiro Kubonishi, Shoji Asakura, Kazutaka Sunami
National Hospital Organization Okayama Medical Center
International Journal of Myeloma 5 (2) 56-56, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-16 The VCD regimen for elderly patients with multiple myeloma : the Fukuoka BMT group observations
Tomohiko Kamimura1, Toshihiro Miyamoto2, Kazuki Tanimoto3, Michitoshi Hashiguchi4, Takatoshi Aoki1, Ilseung Choi5, Naoki Harada8, Ryosuke Ogawa6, Koji Nagafuji7, Koichi Akashi2
1Department of Hematology, Harasanshin Hospital, 2Department of Hematology / Oncology, Kyushu University Hospital, 3Department of Hematology / Oncology, Japanese Red Cross Fukuoka Hospital, 4Department of Hematology, St. Mary's Hospital, 5Department of Hematology, National Hospital Organization Kyushu Cancer Center, 6Japanese Community Health Care Organization, Kyushu Hospital, 7Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 8Department of Internal Medicine, Chihaya Hospital
International Journal of Myeloma 5 (2) 57-57, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-17 A retrospective analysis of the symptomatic multiple myeloma treated by CyBorD in our hospital
Junnosuke Uchihara, Hitoshi Arakaki
Naha city hospital
International Journal of Myeloma 5 (2) 58-58, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-18 Rapid reduction in iFLC predicts achievement of VGPR or better after 4 cycles of VCD treatment
Masahiro Takeuchi1, Atsuko Yamazaki1, Yasuhito Suehara2, Manabu Fujisawa2, Erika Matsuura3, Yusuke Takeda1, Yoshikazu Utsu4, Kazuhisa Fujikawa7, Masahiro Onoda6, Shinichi Ozawa5, Hiroyuki Takamatsu3, Kosei Matsue2, Chiaki Nakaseko1, Hisashi Wakita4
1Department of Hematology, Chiba University Hospital, 2Division of Hematology, Kameda Medical Center, 3Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, 4The Department of Hematology and Oncology, Narita Red Cross Hospital, 5Department of Internal Medicine, Funabashi Central Hospital, 6Department of Internal Medicine, Chiba Aoba Municipal Hospital, 7Department of Hematology, Chibaken Saiseikai Narashino Hospital
International Journal of Myeloma 5 (2) 59-59, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-19 Weekly bortezomib + DEX therapy for elderly patients with relapsed or refractory myeloma (JMSG-0902)
Shuji Ozaki1, Hiroyuki Hata2, Masahiro Abe3, Takayuki Saitoh4, Ichiro Hanamura5, Hiroki Yano6, Kazutaka Sunami7, Hiroshi Kosugi8, Morio Sawamura9, Tomonori Nakazato10, Taro Masunari11, Mayumi Mori12, Toshiyuki Takagi13, Kazuyuki Shimizu14
1Department of Hematology, Tokushima Prefectural Central Hospital, 2Division of Informative Clinical Sciences, Kumamoto University, 3Department of Medicine and Bioregulatory Sciences, University of Tokushima, 4Department of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, 5Department of Hematology, Aichi Medical University, 6Department of Hematology, Kainan Hospital, Aichi Prefectural Welfare Federation of Agricultural Cooperatives, 7Department of Hematology, NHO Okayama Medical Center, 8Department of Hematology, Ogaki Municipal Hospital, 9Department of Hematology, NHO Nishigunma Hospital, 10Department of Hematology, Yokohama Municipal Citizen's Hospital, 11Department of Hematology, Chugoku Central Hospital, 12Tama-Hokubu Medical Center, 13Department of Hematology and Oncology, Kimitsu Chuo Hospital, 14Department of Hematology, Tokai Central Hospital
International Journal of Myeloma 5 (2) 60-60, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-20 Long-term bortezomib therapy for multiple myeloma - retrospective analysis -
Natsue Furuta, Takayuki Hirose, Yosuke Imai, Takuro Ishiguro, Takaaki Chou
Department of Internal medicine, Niigata Cancer Center Hospital
International Journal of Myeloma 5 (2) 61-61, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-21 Successful management of transplant-ineligible patients with RR-MM using a modified bortezomib
Michihide Tokuhira, Yuta Kimura, Yasuyuki Takahashi, Tatsuki Tomikawa, Morihiko Sagawa, Tomoe Nemoto, Takayuki Tabayashi, Reiko Watanabe, Masahiro Kizaki
Saitama Medical Center. Saitama Medical University
International Journal of Myeloma 5 (2) 62-62, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-22 Factors associated with physicians' choice of the VCD regimen for elderly patients
Noriko Yokota1, Hiromi Kuramoto2, Tomohiko Kamimura3, Toshihiro Miyamoto4
1Department of Nursing, Harasanshin Hospital, 2Department of Nursing, Japan Community Health Care Organization, Kyushu Hospital, 3Department of Hematology, Harasanshin Hospital, 4Department of Hematology / Oncology, Kyushu University Hospital
International Journal of Myeloma 5 (2) 63-63, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-23 Hemodialysis-requiring acute kidney injury after bortezomib treatment
Shinya Okuda, Chiaki Takebayashi, Koichi Sugimoto
Department of hematology and oncology, JR Tokyo general hospital
International Journal of Myeloma 5 (2) 64-64, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-24 The molecular mechanism of PDPK1 overexpression in multiple myeloma
Shotaro Tatekawa1, Yoshiaki Chinen1, Yuji Shimura1, Hisao Nagoshi1, Tsutomu Kobayashi1, Eri Kawata2, Nobuhiko Uoshima2, Hiroshi Handa3, Junya Kuroda1, Masafumi Taniwaki1
1Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 2Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, 3Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
International Journal of Myeloma 5 (2) 65-65, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-25 Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma
Yoshiaki Chinen1, Junya Kuroda1, Yuji Shimura1, Hisao Nagoshi1, Masaki Ri2, Eri Kawata3, Tsutomu Kobayashi1, Shigeo Horiike1, Shinsuke Iida2, Masafumi Taniwaki1
1Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 2Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 3Department of Hematology, Japanese Red Cross Kyoto Daini Hospital
International Journal of Myeloma 5 (2) 66-66, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-26 Reverse signaling and clinical impact of B7-H1 (PD-L1) molecules expressed on myeloma cells
Mariko Ishibashi1, Hideto Tamura1, Mika Sunakawa1, Atsushi Isoda2, Morio Matsumoto2, Makoto Sasaki3, Norio Komatsu3, Hiroshi Handa4, Yoichi Imai5, Sakae Tanosaki6, Shigeki Ito7, Yoji Ishida7, Michiaki Koike8, Koichi Inokuchi1
1Division of Hematology, Department of Medicine, Nippon Medical School, 2Department of Hematology, National Hospital Organization Nishigunma National Hospital, 3Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, 4Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, 5Department of Hematology, Tokyo Women's Medical University, 6Department of Hematology, Fraternity Memorial Hospital, 7Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicin, 8Department of Hematology, Juntendo University Shizuoka Hospital
International Journal of Myeloma 5 (2) 67-67, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-27 Expression and function of SLAM family molecules SLAMF3 and SLAMF7 in myeloma
Akiko Yamada1, Hideto Tamura1, Mariko Ishibashi1, Atsushi Isoda2, Makoto Sasaki3, Hiroshi Handa4, Yoichi Imai5, Michiaki Koike8, Shigeki Ito7, Keiichi Moriya1, Asaka Onodera1, Namiko Okuyama1, Yasuko Hamada1, Toshio Asayama1, Norio Komatsu3, Junji Tanaka5, Yoji Ishida7, Sakae Tanosaki6, Koichi Inokuchi1
1Division of Hematology, Department of Medicine, Nippon Medical School, 2Department of Hematology, National Hospital Organization Nishigunma National Hospital, 3Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, 4Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, 5Department of Hematology, Tokyo Women's Medical University, 6Department of Hematology, Fraternity Memorial Hospital, 7Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, 8Department of Hematology, Juntendo University Shizuoka Hospital
International Journal of Myeloma 5 (2) 68-68, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-28 Poly (ADP-ribose) polymerase-1 is involved in the pathogenesis of multiple myeloma
Takayuki Saitoh1, Yusuke Minato2, Tetsuhiro Kasamatsu1, Hiroshi Handa3, Hirokazu Murakami1
1Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 2Department of Virology and Preventive Medicine, Gunma University Graduate School of Medicine, 3Department of Hematology, Gunma University
International Journal of Myeloma 5 (2) 69-69, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-29 BCL6 induces S phase arrest and attenuates DNA damage response in myeloma cells.
Makiko Takizawa1, Kenichi Tahara1, Atsushi Isoda2, Morio Matsumoto2, Morio Sawamura2, Takuma Ishizaki1, Takeki Mitsui1, Hiromi Koiso3, Akihiko Yokohama4, Norifumi Tsukamoto3, Takayuki Saitoh5, Hirokazu Murakami5, Hiroshi Handa1
1Department of Medicine and Clinical Science, Graduate School of Medicine, Gunma University, 2National Hospital Organization, Nishigunma National Hospital, 3Oncology Center, Gunma University Hospital, 4Division of Blood Transfusion Service, Gunma University Hospital, 5Department of Laboratory Science, Graduate School of Health Sience, Gunma University
International Journal of Myeloma 5 (2) 70-70, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-30 TAK-1 is a pivotal therapeutic target against myeloma tumor progression and bone destruction.
Jumpei Teramachi1,2, Masahiro Hiasa1,3, Asuka Oda1, Takeshi Harada1, Ryota Amachi1,4, Hirofumi Tenshin1,4, Shingen Nakamura1, Hirokazu Miki1, Shiro Fujii1, Kumiko Kagawa1, Itsuro Endo1, Toshio Matsumoto5, Masahiro Abe1
1Department of Medicine and Bioregulatory Sciences, Institute of Health Biosciences, Tokushima University Graduate School, 2Department of Histology and Oral Histology, Institute of Health Biosciences, Tokushima University Graduate School, 3Department of Biomaterials and Bioengineering, Institute of Health Biosciences, Tokushima University Graduate School, 4Department of Orthodontics and Dentofacial Orthopedics, Institute of Health Biosciences, Tokushima University Graduate School, 5Fujii Memorial Institute of Medical Sciences, Tokushima University
International Journal of Myeloma 5 (2) 71-71, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-31 PU.1 is the tumor suppressor for mature B and plasma cells in vivo
Shinya Endo1, Hiromichi Yuki1, Yoshihiro Komohara2, Shikiko Ueno1, Nao Nishimura1, Niina Ueno1, Hiro Tatetsu1, Shiho Fujiwara1, Naoko Wada1, Shinya Hirata1, Motohiro Takeya2, Hiroyuki Hata3, Seiji Okada4, Hiroaki Mitsuya1, Yutaka Okuno1
1Department of Hematology, Kumamoto University School of Medicine, 2Department of Cell Pathology, Kumamoto University of Medicine, 3Graduate School of Health Sciences, Division of Informative Clinical Sciences, Kumamoto University School of Medicine, 4Division of Hematopoiesis, Center for AIDS Research, Kumamoto University
International Journal of Myeloma 5 (2) 72-72, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-32 Anti-tumor Effects of PU.1 against Human Multiple Myeloma Cells in Xenograft Mouse Models
Nao Nishimura1, Shinya Endo1, Niina Ueno1, Hiromichi Yuki1, Shikiko Ueno1, Hiroyuki Hata2, Hiroaki Mitsuya1, Yutaka Okuno1
1Department of Hematology, Kumamoto University School of Medicine, 2Graduate School of Health Sciences, Division of Informative Clinical Sciences, Kumamoto University School of Medicine
International Journal of Myeloma 5 (2) 73-73, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-33 Clinical significance of growth factors IL-6 & IGF-1 and their receptors in myeloma
Keiichi Moriya1, Mariko Ishibashi1, Hideto Tamura1, Hiroshi Handa2, Makoto Sasaki3, Atsushi Isoda4, Yoichi Imai5, Shigeki Ito6, Sakae Tanosaki7, Koichi Inokuchi1, Norio Komatsu3, Morio Matsumoto4, Junji Tanaka5, Yoji Ishida6, Michiaki Koike8
1Division of Hematology, Department of Medicine, Nippon Medical School, 2Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, 3Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, 4Department of Hematology, National Hospital Organization Nishigunma National Hospital, 5Department of Hematology, Tokyo Women's Medical University, 6Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, 7Department of Hematology, Fraternity Memorial Hospital, 8Department of Hematology, Juntendo University Shizuoka Hospital
International Journal of Myeloma 5 (2) 74-74, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-34 Kinetics of serum free light chain during relapse in patients with intact immunoglobulin myeloma
Shin-ichi Fuchida, Akira Okano, Mayumi Hatsuse, Satoshi Murakami, Chihiro Shimazaki
Department of Hematology, Kyoto Kuramaguchi Medical Center
International Journal of Myeloma 5 (2) 75-75, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-35 Impact of Myc Gene-Related Aberration in Multiple Myeloma
Naohiro Sekiguchi, Akihisa Nagata, Miwa Kurimoto, Satoshi Noto, Naoki Takezako
National Hospital Organization Disaster Medical Center Hematology Division
International Journal of Myeloma 5 (2) 76-76, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-36 Molecular diagnostics of drug resistant multiple myeloma cases using next generation sequencing
Hiroshi Ikeda1,2, Yuka Aoki1, Toshiaki Hayashi1, Tadao Ishida1, Yasuhisa Shinomura1, Yasushi Sasaki1,2
1Gastroenterology, Rheumatology, clinical immunology, 2Resarch institute for frontier medicine
International Journal of Myeloma 5 (2) 77-77, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-37 Clonal switch in multiple myeloma
Yuichi Nakamura1, Yuu Akuzawa1, Yoshihiro Ito1, Naoki Wakimoto1, Emi Kakegawa1, Yumiko Uchida1, Shigehisa Mori1, Masami Bessho1, Mieko Doi2, Hidekazu Kayano2
1Department of Hematology, Saitama Medical University Hospital, 2Department of Pathology, Saitama Medical University Hospital
International Journal of Myeloma 5 (2) 78-78, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-38 EBER-positive multiple myeloma with rheumatoid arthritis with immunosuppressants
Yasunobu Sekiguchi1, Kunimoto Ichikawa1, Haruko Takizawa1, Mutsumi Wakabayashi1, Keiji Sugimoto1, Norio Komatsu2, Masaaki Noguchi1
1Department of Hematology, Juntendo University Urayasu Hospital, 2Department of Hematologu, Juntendo University Hospital
International Journal of Myeloma 5 (2) 79-79, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-39 A case diagnosed as IgG-lammda type multiple myeloma and Hodgkin lymphoma concurrently
Kazuhito Suzuki, Shingo Yano, Yasuhiro Arakawa, Takaki Shimada, Yuichi Yahagi, Yoji Ogasarwara, Katsuki Sugiyama, Shinobu Takahara, Takeshi Saito, Jiro Minami, Hiroki Yokoyama, Yutaro Kamiyama, Atsushi Katsube, Noriyuki Morikawa, Keisuke Aiba
Division of Clinical Oncology / Hematology, the Jikei University School of Medicine
International Journal of Myeloma 5 (2) 80-80, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-40 Two cases of plasmacytic neoplasms associated with refractory immune thrombocytopenia
Kayo Toishigawa, Mitsuhiro Itagaki, Koji Iwato, Hideki Asaoku, Tetsuro Ochi, Takeshi Okatani, Ryota Imanaka, Kohei Kyo, Yuta Katayama, Taiichi Kyo
Hiroshima Red Cross Hospital & Atomic-bomb Survivor Hospital
International Journal of Myeloma 5 (2) 81-81, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-41 Clinical variety of the IgM type monoclonal γ-globulin blood diseases
Shunsuke Yokota1, Miho Kasuga2, Masahiro Ikeda3, Sumito Shingaki3, Kenshi Miyazaki3, Sosuke Meshiduka3, Yumiko Yoshiki3, Yu Abe3, Nobuhiro Tsukada3, Kenshi Suzuki3
1Japanese Red Cross Medical Centor, Junior Resident, 2Keio University, Faculty of Pharmacy, 3Japanese Red Cross Medical Centor, Department of Hematology
International Journal of Myeloma 5 (2) 82-82, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-42 A multicenter retrospective study of patients with Waldenstrom macroglobulinemia in Japan
Akio Saito1, Atsushi Isoda2, Akihiko Yokohama3, Hiroshi Handa3, Norifumi Tsukamoto3, Yutaka Tsukune4, Makoto Sasaki4, Morio Matsumoto2, Shigeki Ito5, Michiaki Koike6, Kayoko Murayama7, Kei-ichi Moriya8, Hideto Tamura8, Hirotaka Nakahashi9, Sakae Tanosaki10, Tohru Sakura11, Masamitsu Karasawa12, Masaru Kojima13, Naoya Nakamura14, Hirokazu Murakami15
1Department of Hematology, Fujioka general hospital, 2Department of Hematology, National Hospital Organization Nishigunma National Hospital, 3Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, 4Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, 5Department of Oncology, Iwate Medical University, 6Department of Hematology, Juntendo University Shizuoka Hospital, 7Department of Hematology, Gunma Cancer Center, 8Division of Hematology, Department of Internal Medicine, Nippon Medical School, 9Department of Hematology, Fukaya Red Closs Hospital, 10Department of Hematology, The Fraternity Memorial Hospital, 11Gunmaken Saiseikai Maebashi Hospital, 12Department of Hematology, Usui Hospital, 13First Department of Pathology, Dokkyo Medical University, 14Department of Pathology, Tokai University School of Medicine, 15Gunma University Graduate School of Health Scince
International Journal of Myeloma 5 (2) 83-83, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-43 Efficacy of Fludarabine-based regimen for Waldenstrom macroglobulinemia ; single institute experience
Aki Chizuka, Akira Hangaishi, Hideaki Mizuno, Yayoi Ando, Kosuke Yoshioka, Michiko Kida, Kensuke Usuki
NTT Medical Center Tokyo
International Journal of Myeloma 5 (2) 84-84, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-44 The usefulness of labial salivary gland biopsy for diagnosing AL amyloidosis : a retrospective study
Tomotaka Suzuki1,2, Shigeru Kusumoto1, Taro Yamashita4, Arisa Masuda1, Shiori Kinoshita1, Takashi Yoshida1, Fumiko Takami-Mori1,2, Hisashi Takino3, Asahi Ito1, Masaki Ri1, Takashi Ishida1, Hirokazu Komatsu1, Mitsuharu Ueda4, Yukio Ando4, Hiroshi Inagaki3, Shinsuke Iida1
1Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, 2Department of Hematology, Toyokawa City Hospital, 3Department of Pathology and Molecular Diagnostics, 4Department of Neurology, Kumamoto University Graduate School of Medical Sciences
International Journal of Myeloma 5 (2) 85-85, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-45 Possible new disease entity of AL amyloidosis induced by deposition of IGLC2
Eri Fujii1, Masayoshi Tasaki2,3, Taro Yamashita4, Konen Obayashi2, Yukio Ando3, Shinya Endo5, Nao Nishimura5, Yutaka Okuno5, Shiho Fujiwara5, Naoko Wada5, Hiroaki Mitsuya5, Yoshiko Sonoda6, Kennichi Iyama6, Hiroyuki Hata5,7
1Graduate School of Health Sciences, Kumamoto University, 2Department of Morphological and Physiological Sciences, Kumamoto University, 3Faculty of Life Sciences, Department of Neurology, Kumamoto University, 4Diagnostic Unit for Amyloidosis, Kumamoto University Hospital, 5Faculty of Life Sciences, Department of Hematology, Kumamoto University, 6Department of Surgical Pathology, Kumamoto General Hospital, 7Division of Informative Clinical Sciences, Kumamoto University
International Journal of Myeloma 5 (2) 86-86, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-46 Tandem or triplet Auto-PBSCT with 100 mg/m2 of melphalan conditioning for AL amyloidosis.
Akinori Nishikawa1, Yusuke Yamashita1, Takehiro Ohiwa1, Hiroshi Kobata1, Kodai Kuriyama1, Toshiki Mushino1, Hiroki Hosoi1, Shogo Murata1, Kentaro Fukushima2, Kazuo Hatanaka3, Nobuyoshi Hanaoka1, Toshiharu Tamaki2, Hideki Nakakuma1, Takashi Sonoki1
1Department of Hematology / Oncology, Wakayama Medical University, 2Department of Hematology, Rinku General Medical Center, 3Department of Hematology, Osaka Red Cross Hospital
International Journal of Myeloma 5 (2) 87-87, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-47 High dose melphalan and autologous stem cell transplantation for systemic light chain amyloidosis
Nobuhiro Tsukada, Masahiro Ikeda, Sumito Shingaki, Kanji Miyazaki, Sohsuke Meshitsuka, Yumiko Yoshiki, Yuu Abe, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 5 (2) 88-88, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-48 The Efficacy and Long-term Outcomes of ASCT in POEMS Syndrome in Japan
Chiaki Nakaseko1, Chika Kawajiri1, Chikako Ohwada1, Toshihiro Miyamoto2, Taichi Azuma3, Jun Taguchi4, Takehiko Mori5, Yuichi Hasegawa6, Tadakazu Kondo7, Toshiaki Yujiri8, Makoto Yoshimitsu9, Mitsuru Tsudo10, Toshihiro Iwasaki11, Akio Shigematsu12, Ritsuro Suzuki13, Yoshiko Atsuta15, Makoto Hirokawa14, Hisashi Sakamaki15, Emiko Sakaida1
1Department of Hematology, Chiba University Hospital, 2Department of Hematology / Oncology, Kyushu University Hospital, 3Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Hospital, 4Department of Hematology, Japanese Red Cross Shizuoka Hospital, 5Division of Hematology, Keio University School of Medicine, 6Department of Hematology, University of Tsukuba Hospital, 7Department of Hematology and Oncology, Kyoto University Hospital, 8Third Department of Internal of Medicine, Yamaguchi University School of Medicine, 9Department of Hematology and Immunology, Kagoshima University Medical and Dental Hospital, 10Department of Hematology, Osaka Red Cross Hospital, 11Division of Hematology and Oncology, Toyohashi Municipal Hospital, 12Department of Hematology, Hokkaido University Hospital, 13Department of Oncology / Hematology, Shimane University Hospital, 14Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, 15Japanese Data Center for Hematopoietic Cell Transplantation
International Journal of Myeloma 5 (2) 89-89, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-49 Summary of treatment for myeloma in transplant ineligible patients at our hospital (part2)
Takanori Toyama
Miyazaki prefectural Nobeoka Hospital
International Journal of Myeloma 5 (2) 90-90, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-50 Efficacy and safety of dose-adjusted lenalidomide therapy in RRMM patients with renal impairment
Takahiro Mine1, Shigeki Ito2, Maki Asahi3, Tatsuo Oyake3, Wataru Izumida4, Yasuhiko Tsukushi5, Takeshi Sugawara1, Yoji Ishida3
1Department of Hematology / Oncology, Morioka Red-Cross Hospital, 2Department of Medical Oncology, Iwate Medical University School of Medicine, 3Department of Hematology / Oncology, Iwate Medical University School of Medicine, 4Department of Hematology, Iwate Prefectural Ofunato Hospital, 5Department of Hematology, Hachinohe Red-Cross Hospital
International Journal of Myeloma 5 (2) 91-91, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-51 A phase I study of once weekly Btz with Len and Dex for relapsed / refractory multiple myeloma
Haruhito Totani, Masaki Ri, Nana Suzuki, Shinya Hagiwara, Shiori Kinoshita, Takashi Yoshida, Asahi Ito, Shigeru Kusumoto, Takashi Ishida, Hirokazu Komatsu, Shinsuke Iida
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 5 (2) 92-92, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-52 Small-dose of bortezomib, lenalidomide and dexamethasone (sVRD) for maintenance of Multiple Myeloma
Tsutomu Sato1, Hiroyuki Kuroda2, Yasuhiro Nagamachi3, Satoshi Iyama1, Akihito Fujimi4, Yusuke Kamihara1, Yuichi Konuma5, Kazuyuki Murase1, Kohichi Takada1, Rishu Takimoto1, Masayoshi Kobune1, Yasuo Hirayama6, Junji Kato1
1Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, 2Gastroenterology and Hematology / Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital, 3Department of Hematology, Kiyota Hospital, 4Department of Hematology and Oncology, Oji General Hospital, 5Department of Hematology and Oncology, Asahikawa Red Cross Hospital, 6Division of Internal Medicine, Higashi Sapporo Hospital
International Journal of Myeloma 5 (2) 93-93, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-53 Usefulness of cyclophosphamide, lenalidomide, dexamethasone in relapsed and refractory myeloma
Tomonori Hidaka, Akira Kitanaka, Keiichi Akiduki, Masaaki Sekine, Ayako Kamiunten, Takuro Kameda, Kotaro Shide, Yoko Kubuki, Kazuya Shimoda
Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicin, University of Miyazaki
International Journal of Myeloma 5 (2) 94-94, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-54 The efficacy of lenalidomide maintenance therapy for transplant-ineligible patients with myeloma
Hiroyuki Kuroda1, Tsutomu Sato2, Yasuhiro Nagamachi3, Makoto Usami1,2, Koichi Takada2, Satoshi Iyama2, Akihito Fujimi4, Akari Hashimoto2,4, Yuji Kanisawa4, Yasuo Hirayama5, Yuichi Konuma6, Hiroto Horiguchi1, Ken Sato1, Michiko Yamada1, Tomoyuki Abe1, Shigeyuki Fujii1, Masahiro Maeda1, Junji Kato2
1Dept. of Hematology and Oncology, Steel Memorial Muroran Hospital, 2Dept of Medical Oncology / Hematology, Sapporo Medical University, 3Dept. of Hematology, Sapporo Kiyota Hospital, 4Dept. of Hematology and Oncology, Oji General Hospital, 5Dept. of Hematology, Higashi Sapporo Hospital, 6Dept. of Hematology and Oncology, Asahikawa Red Cross Hospital
International Journal of Myeloma 5 (2) 95-95, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-55 Withdrawal of lenalidomide might result in macrophage activation syndrome
Tomonori Shimokawa, Goichi Yoshimoto, Toshihiro Miyamoto, Teppei Sakoda, Takuji Yamauchi, Takahiro Shima, Yasuo Mori, Kenjiro Kamezaki, Koji Kato, Katsuto Takenaka, Hiromi Iwasaki, Koichi Akashi
Department of medicine and biosystemic science kyushu university faculty of medicine
International Journal of Myeloma 5 (2) 96-96, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-56 Phase 1 Study of Ixazomib Alone or in Combination with Rd in Patients with RRMM in Japan
Takaaki Chou1, Kenshi Suzuki2, Hiroshi Handa3, Kenichi Ishizawa4, Takatoshi Takubo5, Takafumi Matsushima5
1Department of Internal Medicine, Niigata Cancer Center Hospital, 2Department of Hematology, Japanese Red Cross Medical Center, 3Department of Hematology, Gunma University Graduate School of Medicine, 4Department of Hematology and Rheumatology, Tohoku University, 5Takeda Pharmaceutical Company Limited
International Journal of Myeloma 5 (2) 97-97, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-57 Phase I / II study of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma
Morio Matsumoto1, Takashi Watanabe2, Kensei Tobinai2, Kenshi Suzuki3, Kazutaka Sunami4, Tadao Ishida5, Kiyoshi Ando6, Takaaki Chou7, Shuji Ozaki8, Masafumi Taniwaki9, Naokuni Uike10, Hirohiko Shibayama11, Kiyohiko Hatake12, Koji Izutsu13, Takayuki Ishikawa14, Shinsuke Iida15
1Department of Hematology, National Hospital Organization Nishigunma National Hospital, 2Department of Hematology, National Cancer Center Hospital, 3Department of Hematology, Japanese Red Cross Medical Center, 4Department of Hematology, National Hospital Organization Okayama Medical Center, 5Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, 6Department of Hematology and Oncology, Tokai University School of Medicine, 7Department of Internal Medicine, Niigata Cancer Center Hospital, 8Department of Hematology, Tokushima Prefectural Central Hospital, 9Division of Hematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 10Department of Hematology, National Hospital Organization Kyushu Cancer Center, 11Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 12Department of Hematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 13Department of Hematology, Toranomon Hospital, 14Department of Hematology, Kobe City Medical Center General Hospital, 15Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 5 (2) 98-98, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-58 Efficacy and safety of denosumab for multiple myeloma
Junichi Kitagawa, Takuro Matsumoto, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Nobuhiro Kanemura, Takeshi Hara, Hisashi Tsurumi
Department hematology, Gifu university
International Journal of Myeloma 5 (2) 99-99, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-59 Analysis of deregulated iron metabolism and iron chelation-induced cytotoxicity in multiple myeloma
Kohichi Takada, Yusuke Kamihara, Tsutomu Sato, Yutaka Kawano, Satoshi Iyama, Kazuyuki Murase, Shohei Kikuchi, Hiroto Horiguchi, Akari Hashimoto, Ayumi Tatekoshi, Rishu Takimoto, Masayoshi Kobune, Junji Kato
Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
International Journal of Myeloma 5 (2) 100-100, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-60 Combination treatment of HSP90 α / β inhibitor and RAS-RAF-MEK-ERK inhibitor for myeloma treatment
Rikio Suzuki1, Shohei Kikuchi2, Yoshikazu Iwasawa3, Kiyoshi Ando4, Teru Hideshima2, Kenneth Anderson2
1Department of Hematology, Ebina General Hospital, 2Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, 3Discovery and Preclinical Research Division, TAIHO PHARMACEUTICAL CO.,LTD., 4Department of Hematology / Oncology, Tokai University School of Medicine
International Journal of Myeloma 5 (2) 101-101, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-61 Suppression of bone resorption enhanced in myeloma by Pim inhibition
Jumpei Teramachi1,2, Masahiro Hiasa1,3, Asuka Oda1, Takeshi Harada1, Hirofumi Tenshin1,4, Ryota Amachi1,4, Hirokazu Miki1, Shingen Nakamura1, Shiro Fujii1, Kumiko Kagawa1, Itsuro Endo1, Toshio Matsumoto5, Masahiro Abe1
1Department of Medicine and Bioregulatory Sciences, Institute of Health Biosciences, Tokushima University Graduate School, 2Department of Histology and Oral Histology, Institute of Health Biosciences, Tokushima University Graduate School, 3Department of Biomaterials and Bioengineering, Institute of Health Biosciences, Tokushima University Graduate School, 4Department of Orthodontics and Dentofacial Orthopedics, Institute of Health Biosciences, Tokushima University Graduate School, 5Fujii Memorial Institute of Medical Sciences, Tokushima University
International Journal of Myeloma 5 (2) 102-102, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-62 Combinatory effects of Pim inhibitors with clinically available anti-myeloma agents
Shingen Nakamura1, Hirokazu Miki2, Asuka Oda1, Jyunpei Teramachi3, Ryouta Amachi4, Derek Hanson1, Hirofumi Tenshin4, Kimiko Sogabe1, Hikaru Fujino1, Tomoko Maruhashi1, Shiro Fujii1, Kumiko Kagawa1, Masahiro Abe1
1Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, 2Department of Transfusion Medicine and cell therapy, Tokushima University Hospital, 3Department of Histology and Oral Histology, Institute of Health Biosciences, The University of Tokushima Graduate School, 4Department of Orthodontics and Dentofacial Orthopedics, Institute of Health Biosciences, The University of Tokushima Graduate School
International Journal of Myeloma 5 (2) 103-103, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-63 EZH2 inhibition as a novel therapeutic strategy in multiple myeloma
Naoya Mimura1, Rizq Ola2, Tohru Iseki1, Chiaki Nakaseko3, Atsushi Iwama2
1Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 2Department of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, 3Department of Hematology, Chiba University Hospital
International Journal of Myeloma 5 (2) 104-104, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-64 Survivin inhibitor YM155 exerts antiproliferative activity against myeloma including dormant cells.
Miyuki Ookura, Shinji Kishi, Takahiro Yamauchi, Takanori Ueda, Akira Yoshida
Department of Hematology and Oncology, University of Fukui
International Journal of Myeloma 5 (2) 105-105, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O-65 Effective impairment of myeloma progenitors by hyperthermia
Hirokazu Miki1, Takeshi Harada2, Shiro Fujii2, Ryota Amachi3, Hirofumi Tenshin3, Keiichiro Watanabe3, Derek Hanson2, Jumpei Teramachi4, Hikaru Yagi2, Kimiko Sogabe2, Mamiko Takahashi2, Tomoko Maruhashi2, Kengo Udaka2, Shingen Nakamura2, Kumiko Kagawa2, Michinori Nakamura5, Toshio Matsumoto6, Masahiro Abe2
1Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 2Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences, 3Department of Orthodontics and Dentofacial Orthopedics, The University of Tokushima Graduate School of Oral Science, 4Department of Histology and Oral Histology, The University of Tokushima Graduate School of Oral Science, 5Department of Anatomy and Cell Biology Medical Informations, The University of Tokushima Graduate School, 6Fujii Memorial Institute for Medical Reseach, The University of Tokushima
International Journal of Myeloma 5 (2) 106-106, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
Thalidomide and other IMiDs in maintenance therapy
A.Keith Stewart
Anna Maria and Vasek Polak Professor of Cancer Research, Dean for Research, Division of Hematology-Oncology, Mayo Clinic
International Journal of Myeloma 5 (2) 108-108, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
Pomalidomide, a new treatment option in relapsed and refractory Multiple Myeloma
Katja Weisel
Universitatsklinikum Tubingen Medizinische Klinik und Poliklinik
International Journal of Myeloma 5 (2) 109-109, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
New agents for the treatment of newly-diagnosed multiple myeloma
Yasushi Takamatsu
Internal Medicine / Division of Medical Oncology, Hematology and Infectious Diseases, Faculty of Medicine, Fukuoka University
International Journal of Myeloma 5 (2) 110-110, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
Prognostic value of minimal residual disease response assessment in multiple myeloma
Hiroyuki Takamatsu
Cellular Transplantation Biology (Hematology / Respirology), Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University
International Journal of Myeloma 5 (2) 111-111, 2015.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。